DXCM Falls On CGM Rivalry, ZYNE Firms Up, SPPI In Limelight, Big Day Awaits MNKD

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of September 28, 2017.

GAINERS

1. Zynerba Pharmaceuticals Inc. (ZYNE)

Gained 52.50% to close Thursday’s (Sep.28) trading at $9.44.

News: The Company reported positive top line results from its phase II trial of ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome.

In the trial, dubbed FAB-C, ZYN002 cannabidiol gel in pediatric and adolescent patients with Fragile X syndrome met its primary endpoint, achieving a 46% improvement in the total score of Anxiety, Depression, and Mood Scale (ADAMS) at week twelve compared to baseline.

2. Spectrum Pharmaceuticals Inc. (SPPI)

Gained 22.97% to close Thursday’s trading at $13.49.

News: The Company announced that additional interim data from its ongoing phase II study of Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer will be released on October 18, 2017.

In a recent presentation about Poziotinib compassionate use in Non-Small Cell Lung Cancer at MD Anderson Cancer Center, the Company revealed that for a 65 year old non smoking female suffering from Stage IV adenocarcinoma with HER2 exon 20 insertion mutation, treatment with Poziotinib 16mg orally daily for a week improved cough and pain in multiple bone sites. PET/CT scans of the patient taken after 4 weeks of therapy showed significant radiolological response while after 9 weeks of therapy, the patient is stable.

3. Catabasis Pharmaceuticals Inc. (CATB)

Gained 21.86% to close Thursday’s trading at $2.23.

News: The Company will present results from joint research collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society on October 5, 2017.

The poster presentation is titled “Edasalonexent (CAT-1004), an NF-kB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice”.

Edasalonexent is Catabasis’ lead drug candidate for Duchenne muscular dystrophy.
A three-part phase I/II clinical trial investigating the safety and efficacy of Edasalonexent in boys ages 4-7 affected with Duchenne muscular dystrophy (any confirmed mutation), dubbed MoveDMD, is underway.

Part A of the MoveDMD trial evaluated the safety, tolerability and pharmacokinetics of Edasalonexent and showed positive results. Sixteen of the 17 boys enrolled in Part A continued to Part B of the trial, which is a phase II trial that evaluated the safety and efficacy of…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *